Cancers, Vol. 12, Pages 2239: Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
Cancers, Vol. 12, Pages 2239: Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
Cancers doi: 10.3390/cancers12082239
Authors:
Valentina Tuninetti
Marilena Di Napoli
Eleonora Ghisoni
Furio Maggiorotto
Manuela Robella
Giulia Scotto
Gaia Giannone
Margherita Turinetto
Dimitris Siatis
Riccardo Ponzone
Marco Vaira
Michele De Simone
Cono Scaffa
Sandro Pignata
Stefano Greggi
Massimo Di Maio
Giorgio Valabrega
Few retrospective studies have shown a benefit in selected patients affected by heavily pre-treated, platinum-resistant ovarian carcinomas (PROCs) who have undergone cytoreduction at relapse. However, the role of tertiary and quaternary cytoreductive surgery is not fully defined. Our aim was to evaluate survival and surgical morbidity and mortality after maximal cytoreduction in this setting. We evaluated all consecutive patients undergoing cytoreduction for platinum-resistance over an 8-year period (2010–2018) in two different centers. Fifty patients (median age 52.5 years, range 34–75) were included; the median number of previous chemotherapy lines was three (range 1–7) and the median number of previous surgeries was one (range 1–4). Completeness of cytoreduction (CC = 0) was achieved in 22 patients (44%). Rates of major operative morbidity and 30-day mortality were 38% and 8%, respectively. Median fo...
Source: Cancers - Category: Cancer & Oncology Authors: Valentina Tuninetti Marilena Di Napoli Eleonora Ghisoni Furio Maggiorotto Manuela Robella Giulia Scotto Gaia Giannone Margherita Turinetto Dimitris Siatis Riccardo Ponzone Marco Vaira Michele De Simone Cono Scaffa Sandro Pignata Stefano Greggi Massimo Di Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Epithelial Cancer | Ovarian Cancer | Ovaries | Study